IL304392A - 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-4,2,1-thiadiazol-5-yl]benzamide for use in medicine - Google Patents

4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-4,2,1-thiadiazol-5-yl]benzamide for use in medicine

Info

Publication number
IL304392A
IL304392A IL304392A IL30439223A IL304392A IL 304392 A IL304392 A IL 304392A IL 304392 A IL304392 A IL 304392A IL 30439223 A IL30439223 A IL 30439223A IL 304392 A IL304392 A IL 304392A
Authority
IL
Israel
Prior art keywords
thiadiazol
benzamide
chlorophenyl
oxo
chloro
Prior art date
Application number
IL304392A
Other languages
English (en)
Hebrew (he)
Original Assignee
Betagenon Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon Ab filed Critical Betagenon Ab
Publication of IL304392A publication Critical patent/IL304392A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL304392A 2021-01-12 2023-07-11 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-4,2,1-thiadiazol-5-yl]benzamide for use in medicine IL304392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2100352.0A GB202100352D0 (en) 2021-01-12 2021-01-12 New methods
PCT/GB2022/050054 WO2022153042A1 (en) 2021-01-12 2022-01-11 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine

Publications (1)

Publication Number Publication Date
IL304392A true IL304392A (en) 2023-09-01

Family

ID=74667674

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304392A IL304392A (en) 2021-01-12 2023-07-11 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-4,2,1-thiadiazol-5-yl]benzamide for use in medicine

Country Status (12)

Country Link
US (1) US20240082222A1 (https=)
EP (1) EP4277625A1 (https=)
JP (1) JP2024505143A (https=)
KR (1) KR20230159375A (https=)
CN (1) CN117320716A (https=)
AU (1) AU2022208237A1 (https=)
BR (1) BR112023013828A2 (https=)
CA (1) CA3208099A1 (https=)
GB (1) GB202100352D0 (https=)
IL (1) IL304392A (https=)
MX (1) MX2023008263A (https=)
WO (1) WO2022153042A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
WO2025027205A1 (en) * 2023-08-03 2025-02-06 Betagenon Ab Treatment of cancer with the pdk inhibitor 4-chloro-n-(2-(4-chlorobenzyl)-3-oxo-2,3-dihydro-1,2,4-thiadiazol-5-yl)benzamide
WO2025252672A1 (en) * 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
JP5982281B2 (ja) * 2009-07-08 2016-08-31 バルティック バイオ アーベー 医薬として有用な化合物
AU2011281381B2 (en) * 2010-07-21 2015-07-16 Novartis Ag Salt and solvates of a tetrahydroisoquinoline derivative
KR20190009428A (ko) * 2013-10-25 2019-01-28 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
AU2018448511B2 (en) * 2018-11-05 2025-07-03 Betagenon Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
US11691954B2 (en) * 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations

Also Published As

Publication number Publication date
AU2022208237A1 (en) 2023-08-10
CA3208099A1 (en) 2022-07-21
EP4277625A1 (en) 2023-11-22
KR20230159375A (ko) 2023-11-21
WO2022153042A1 (en) 2022-07-21
US20240082222A1 (en) 2024-03-14
CN117320716A (zh) 2023-12-29
AU2022208237A9 (en) 2024-07-25
JP2024505143A (ja) 2024-02-05
MX2023008263A (es) 2023-09-12
BR112023013828A2 (pt) 2023-10-03
GB202100352D0 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
IL304392A (en) 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-4,2,1-thiadiazol-5-yl]benzamide for use in medicine
DK4045038T3 (en) New formulations of 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide
AR016351A1 (es) FORMA CRISTALINA BETA DE LA SAL DE ADICIoN DE ÁCIDO METANSULFoNICO DE 4-(4-METILPIPERAZIN-1-ILMETIL)-N-[4-METIL-3-(4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) FENIL] BENZAMIDA, COMPOSICIoN FARMACÉUTICA, USO DE LA FORMA CRISTALINA PARA LA PREPARACIoN DE UN AGENTE FARMACOLoGICO, Y PROCESOS PARA LA PREPARACIo
NZ598461A (en) Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
BR0308053A (pt) Stents revestidos com n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina
TW200745069A (en) Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use
AR093188A1 (es) Sal y uso medico
JP2016506910A5 (https=)
HK40103810A (en) 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine
HRP20201695T1 (hr) Blokatori natrijevih kanala
NO940274D0 (no) 2-(4-(-azolbutyl)-1-piperazinyl)-5-hydroksy-pyrimidinderivater, deres fremstilling og anvendelse som legemidler
IL283843A (en) (s)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and its pharmaceutically acceptable salts
EP3781197A4 (en) VARIANT ASPARAGINASE POLYPEPTIDES FOR MEDICAL USE
US11744665B2 (en) Modular workspace platform system, accessories therefor, and associated methods
FR2920776B1 (fr) Utilisation de derives de purine pour la fabrication d'un medicament
CR20160172A (es) Ácido {4-[5-(3-cloro-fenoxi)-oxazolo[5,4-d]pirimidin-2-il]-2,6-dimetil-fenoxi}acético para su uso en la prevención o el tratamiento de la lesión renal aguda
CN209152422U (zh) 一种按摩衬垫及护膝
AR043622A1 (es) "2- (butil-1 sulfonilamino) - n- [1 (r) - (6 - metoxipiridin - 3 - il - propil] benzamida ,su uso como un medicamento y preparaciones farmaceuticas que lo comprenden
UY27123A1 (es) Utilización de cromanos
WO2004082582A3 (fr) Utilisation du diazoxide dans le traitement de l'ischemie retinienne
CN103735341B (zh) 骨伤康复器
CN204971612U (zh) 一种创口护理用托盘
ITBS20110140A1 (it) Spatola per stendere un materiale su una superficie
AR035273A1 (es) Pramipexol para el tratamiento del adhd
RU2003119177A (ru) Лекарственный препарат для лечения хронической сердечной недостаточности